Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Merck
AstraZeneca
Argus Health
Baxter
Colorcon

Generated: September 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR METHYLENE BLUE

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for Methylene Blue

Trial ID Title Status Sponsor Phase Summary
NCT00070317 Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer Terminated National Cancer Institute (NCI) N/A This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.
NCT00070317 Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer Terminated Gynecologic Oncology Group N/A This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.
NCT00131599 Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer Unknown status AHS Cancer Control Alberta N/A Cancer of the colon and rectum are the third most common cancers in Canadian males and females. The initial therapy of colorectal cancer is surgery to remove the cancer and nearby lymph glands. If the cancer has spread to the lymph glands there is a high chance that the cancer will come back. To reduce the risk of the cancer recurring, patients are treated with an anticancer drug 5-fluorouracil (5FU) in combination with a vitamin leucovorin (LV). This study will determine if a simple blood test can predict which patients are at risk for developing side effects from this chemotherapy. In addition, participants of this study will be followed to determine if this same blood test will predict which patients will have their cancer relapse.
>Trial ID >Title >Status >Phase >Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Methylene Blue

Condition Name

Condition Name for Methylene Blue
Intervention Trials
Malaria 4
Prostate Cancer 3
Breast Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Methylene Blue
Intervention Trials
Malaria 6
Prostatic Neoplasms 5
Breast Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Methylene Blue

Trials by Country

Trials by Country for Methylene Blue
Location Trials
United States 101
China 22
Canada 9
Brazil 6
Burkina Faso 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Methylene Blue
Location Trials
Pennsylvania 7
New York 6
Maryland 6
Texas 6
California 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Methylene Blue

Clinical Trial Phase

Clinical Trial Phase for Methylene Blue
Clinical Trial Phase Trials
Phase 4 7
Phase 3 8
Phase 2/Phase 3 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Methylene Blue
Clinical Trial Phase Trials
Completed 30
Recruiting 16
Not yet recruiting 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Methylene Blue

Sponsor Name

Sponsor Name for Methylene Blue
Sponsor Trials
Heidelberg University 7
National Cancer Institute (NCI) 7
Isofol Medical AB 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Methylene Blue
Sponsor Trials
Other 110
Industry 17
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Merck
Farmers Insurance
Federal Trade Commission
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.